Literature DB >> 24907079

Transthoracic echocardiography as a measuring and guiding tool for transcatheter device closure of secundum atrial septal defect in young children.

Nadeem Sadiq1, Maad Ullah, Mehboob Sultan, Khurram Akhtar.   

Abstract

OBJECTIVE: To analyze the effectiveness of transthoracic echocardiography (TTE) for device closure of secundum atrial septal defect in children ≤5 years old. STUDY
DESIGN: Quasiexperimental study. STUDY LOCATION AND DURATION: The study was conducted at Armed Forces Institute of Cardiology and National Institute of Heart Diseases from December 1, 2010 to December 31, 2012. PATIENTS AND METHODS: During the study period, a total of 48 children ≤5 years old underwent device closure of secundum atrial septal defect. The indications for closure were: elective closure in 31; parental anxiety in 10; frequent respiratory infection in 4; severe pulmonary stenosis in 2; and severe mitral stenosis in 1 patient. The procedure was carried out under general or local anesthesia with TTE and fluoroscopic guidance. TTE was the primary tool used for measurement of defect and estimation of occluder size as well as guiding equipment during device deployment in all patients.
RESULTS: A total of 47/48 patients (97.9%) had successful closure of secundum atrial septal defect. The mean age was 4.1 ± .68 years (range, 2.5-5 years) and 28/48 patients (58.4%) were female. The defect size and occluders used were between 5-20 mm (mean, 12 ± 3.5 mm) and 8-22 mm (mean, 15 ± 3.9 mm), respectively. Three patients had simultaneous procedures comprising pulmonary balloon valvuloplasty in 2 patients and percutaneous transmitral commissurotomy in 1 patient. The device embolization occurred in 1 patient; the device was retrieved percutaneously and the patient was referred for surgical closure. The minor complications were residual leak (n = 1), transient bradycardia (n = 4), and first-degree heart block (n = 1). The median procedure time was 30 min (range, 15-100 min) and median fluoroscopic time was 6 min (range, 1.50-45 min). There were no emergency surgical explorations, cardiac perforations, vascular injuries, or deaths during this period.
CONCLUSION: TTE can be used as a primary tool for the measurement of atrial septal defect and guidance during device deployment in young children by skilled and professional hands, yet more experience is awaited.

Entities:  

Mesh:

Year:  2014        PMID: 24907079

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  5 in total

1.  Initial Experience with the Nit-Occlud ASD-R: Short-Term Results.

Authors:  Mustafa Orhan Bulut; Ilker Kemal Yucel; Mehmet Kucuk; Sevket Balli; Evic Zeynep Basar; Ahmet Celebi
Journal:  Pediatr Cardiol       Date:  2016-06-09       Impact factor: 1.655

2.  Appropriate device selection for transcatheter atrial septal defect closure using three-dimensional transesophageal echocardiography.

Authors:  Hiroki Kitakata; Yuji Itabashi; Hideaki Kanazawa; Kotaro Miura; Mai Kimura; Keitaro Shinada; Marjolein C de Jongh; Jin Endo; Hikaru Tsuruta; Mitsushige Murata; Akio Kawamura; Mitsuru Murata; Keiichi Fukuda
Journal:  Int J Cardiovasc Imaging       Date:  2020-11-05       Impact factor: 2.357

3.  Transcatheter perimembranous ventricular septal defect closure under transthoracic echocardiographic guidance without fluoroscopy.

Authors:  Shouzheng Wang; Wenbin Ouyang; Yao Liu; Fengwen Zhang; Gaili Guo; Guangzhi Zhao; Xiangbin Pan
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  Percutaneous device closure of atrial septal defect with totally transthoracic echocardiography guide, without x-ray machine.

Authors:  Hua Cao; Qiang Chen; Gui-Can Zhang; Liang-Wan Chen; Zhi-Huang Qiu; Heng Lu
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

5.  Transcatheter device closure of atrial septal defects guided completely by transthoracic echocardiography: A single cardiac center experience with 152 cases.

Authors:  Qiang Chen; Hua Cao; Gui Can Zhang; Liang Wan Chen; Heng Lu; Lin Li Yu
Journal:  Anatol J Cardiol       Date:  2018-12       Impact factor: 1.596

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.